Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
| Autor: | Filiz Vural, Melda Cömert Özkan, Emin Kaya, Mehmet Sönmez, Mehmet Turgut, İrfan YavaŞoĞlu, Idris Ince, Birol Guvenc, Mahmut Töbü, İsmet Aydoğdu, Güray Saydam, Gülsüm Özet, Volkan Karakuş, Fusun Gediz, Cem Kis, Nur Soyer, İbrahim C. Haznedaroğlu, Alİ Pİr, Gül İlhan, Rıdvan Ali, MÜzeyyen Aslaner, Gökhan Özgür, Fahri Şahin, Asu Fergun Yilmaz, Funda Ceran, Isabel Raika Durusoy Onmuş |
|---|---|
| Přispěvatelé: | OMÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turgut, Mehmet |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Ruxolitinib Turkey ruxolitinib Constitutional symptoms Myelofibrosis myelofibrosis World-Health-Organization survival Gastroenterology Article Median follow-up General & Internal Medicine Internal medicine Diagnosis Nitriles medicine Overall survival Humans In patient Available Therapy Adverse effect International Working Group Retrospective Studies treatment business.industry General Medicine Comfort-Ii Classification medicine.disease adverse events Clinical Practice Pyrimidines Myeloid Neoplasms Primary Myelofibrosis Japanese Patients Pyrazoles Myeloproliferative Neoplasms Female Open-Label business medicine.drug |
| Zdroj: | Turkish Journal of Medical Sciences |
| ISSN: | 1303-6165 |
| Popis: | Tam Metin / Full Text Q4 SCI-Expanded WOS:000668244900016 PMID: 33315343 The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|